Statin-related myopathy: A review of the literature

• Autores: Cristóbal Gallego Muñoz, Francisco Javier Ferreira Alfaya, Nieves Guerrero Navarro
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 3, 2016, págs. 182-188
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction: The use of statins for cardiovascular disease prevention is clearly supported by clinical evidence. However, many alerts have been reported about of statin risks. Among them the by far most common complication is myopathy, ranging from common but clinically benign myalgia to rare but life threatening rhabdomyolysis. The aims of the present review are (i) to descrive the clinical features of statin myopathy, (ii) to underline criteria for identification of at-risk patients and (iii) to discuss the practical management of this issue.

    Method: A systematic review of the published literature until September 2015 was undertaken. The searched databases were: MEDLINE, EMBASE, Cochrane Library and Web of Science.

    Results: The common clinical symptoms of statin-related myopathy range from complaints of mild fatigue to fulminant rhabdomyolysis. The risk factors are numerous and of different nature. Baseline measurement and monitoring of CK and the possibility of other therapeutic alternatives can be contemplated.

    Conclusion: Clinicians and pharmacists should operate a rationale screening of patients at potential risk before starting any therapy with statins and consider alternative strategies when such side effect occurs